Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The unequal scramble for coronavirus vaccines — by the numbers

Wealthy countries have already pre-ordered more than two billion doses.
  1. Ewen Callaway
    View author publications

    You can also search for this author in PubMed  Google Scholar

Three workers in protective clothing work on a bioreactor in a vaccine producing facility in Pune, India

Researchers at the Serum Institute of India in Pune are manufacturing a COVID-19 vaccine, developed at Oxford University. Credit: Atul Loke/NYT/Redux/eyevine

Wealthy countries have struck deals to buy more than two billion doses of coronavirus vaccine in a scramble that could leave limited supplies in the coming year. Meanwhile, an international effort to acquire vaccines for low- and middle-income countries is struggling to gain traction.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 584, 506-507 (2020)

doi: https://doi.org/10.1038/d41586-020-02450-x

Updates & Corrections

  • Update 27 August 2020: The graphic entitled ‘Best and worst supplied’ has been updated with new figures from Airfinity.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links